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Abstract Results 
Homologous recombination is a mechanism conducted to exchange 
nucleotides between two similar sequences, which allows researchers to 
knock out and add genetic sequences of their interest in vaccinia virus 
(VACV). In this study, a Western Reserve  VACV strain with inserted genes 
encoding Red Florescence Protein (RFP) and Green Florescence Protein 
(GFP), will be targeted and replaced with the Thymidine Kinase gene, J2R 
as well as C11 gene, respectively. This will set the foundation for continual 
removal of genes as well as additions to make a virus that will more 
effectively target cancer cells without affecting healthy cells. To conduct 
this experiment, the J2R gene was constructed via overlapping PCR and 
shared homology with the Western Reserve strain allowing for the 
homologous recombination to occur. HeLa cells are then infected and 
transfected with the VACV and the J2R overlapping PCR fragment, 
respectively. The transfection of the overlapping J2R PCR fragment into the 
infected HeLa cells will allow the virus to recombine. The infected cells are 
then collected and used to infect BS-C-1 cells, which allowed formation of 
plaques. The green (GFP) plaques without RFP are to be collected and 
undergo several rounds of purification. Upon purification, the DNA will be 
extracted using an SQ Blood Kit and enhanced via PCR. To confirm the 
virus recombined appropriately, the DNA will be sent out for sequencing 
and the procedure will be repeated for the replacement of GFP with C11 
overlapping PCR fragment. Upon successful recombinant virus 
construction, the virus will undergo additional knockouts as well as 




Conclusion and Future Research 
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B. Expected Recombination with Overlapping Primer   
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Figure 1: Schematics of Red Florescence Protein integrated in VACV and Expected 
Recombination with Overlapping Primer.  
A. Schematic contains the current schematic of the Western Reserve Vaccinia Virus with 
the Red Florescent protein integrated along with a G8R promoter. The primers are 
included, two of which were design for overlapping PCR. 
B. The expected recombination of the vaccinia virus with the overlapping PCR segment. 
This then allows the J2R upstream and downstream green segments to rejoin. 
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Figure 2: Screening and Conformation of 
Overlapping PCR Fragment using Gel 
Electrophoresis 
The electrophoresis gel demonstrates the correct 
fragment from the overlapping PCR reaction. 
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A. DNA Sequence Construct of Red Florescent Protein within the J2R gene 














B. Expected Recombination Map of DNA sequence of J2R gene with the 














Figure 3: DNA sequences of the initial Vaccinia Virus with RFP and the 
expected recombination map of the J2R gene. 
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